

Serina Therapeutics Announces Dr. Randall Moreadith, President and CEO, Will Present at BIO CEO and Investor Annual Meeting February 11-12th 2019 in New York, NY

Huntsville, AL, February 8th 2019

Serina Therapeutics, Inc., a pharmaceutical research and development company that has developed a proprietary, patented polymer technology platform for drug development based upon polyoxazoline (POZ[™]), announced today that Dr. Randall Moreadith will be presenting at the annual BIO CEO and Investor Conference in New York February 11th, 2019. BIO CEO and Investor occurs annually in NYC and brings over 1,500 investors and CEOs from across the biotechnology sector together over a two day period.

“I am very excited about the update I will present this year at the annual BIO CEO and Investor Conference in New York. We have a new pipeline program that is aimed at advanced Parkinson’s disease patients and we expect this product candidate to enter IND-enabling studies in the second quarter of 2019,” stated Dr. Moreadith.

Dr. Moreadith will present a session entitled “The Era of Once Weekly Continuous Drug Delivery in Parkinson’s Disease is Here”. This presentation will summarize the results of the Phase Ia trial with SER-214, and a new product candidate POZ-apomorphine. Apomorphine is the most potent dopamine agonist known, and is currently administered via an electronic device through an insulin infusion set. This requires daily administration and assistance from a healthcare provider. The current formulation of apomorphine (APO-Go) is confounded by significant skin irritation that can lead to nodules in over 40% of patients, and in some rare instances, skin necrosis.

Serina’s approach to solve this problem was to attach apomorphine to a polymer of POZ stably employing its proprietary linker technology – such that the apomorphine is not released until the polymer conjugate reaches the vascular compartment. A subcutaneous injection of POZ-apomorphine did not promote any skin irritation in experimental animals, and provided seven days of continuous delivery of the attached apomorphine when plasma levels were determined.

“This product candidate is a potential breakthrough therapy for patients with advanced Parkinson’s disease,” according to Dr. Moreadith.

Serina Therapeutics Pipeline

Serina Therapeutics has a robust pipeline of poly(oxazoline) polymer conjugates. The most advanced product candidate is SER-214, a first-in-class drug candidate that delivers rotigotine continuously following a single weekly subcutaneous administration. The Phase Ia program in patients with Parkinson’s disease has completed enrollment, and Serina plans to advance SER-214 into Phase II development in 2019 for both Parkinson’s disease and restless leg syndrome. In addition to this product candidate for early Parkinson’s disease, Serina has recently advanced POZ-apomorphine (tentatively identified as SER-241) – a polymer conjugate of apomorphine, the most potent dopamine agonist known – into pre-clinical studies in monkeys. SER-241 is on track to enter Phase I development in late 2019. SER-241 will be developed for advanced patients with Parkinson’s disease who have significant daily “off” periods not controlled with optimal oral therapy. SER-241 is designed to deliver apomorphine continuously over a one week period following a single SC injection, and early studies in the monkey show this occurs without skin inflammation. Inflammatory skin reactions, including abscess formation,

can occur with the current formulations of apomorphine that are administered as a daily 12-16 hour infusion (APO-Go). These formulations lead to a high incidence of nodule formation.

In addition to a growing pipeline of proprietary programs focused on movement disorders, pain and epilepsy Serina is currently collaborating with leading pharmaceutical companies to further unlock the promise of the POZ™ platform and is actively seeking new partnership opportunities.

About Serina

Serina Therapeutics is a privately held pharmaceutical company located at the Hudson-Alpha Institute for Biotechnology in Huntsville, AL that is developing novel polymer therapeutics based on its proprietary polyoxazoline technology. The founders and managers of Serina were formerly the key principals of Shearwater Polymers, a company that enabled fourteen approved polyethylene glycol (PEG) products for various pharmaceutical partners. POZ™ technology provides strong differential characteristics that may demonstrate improved safety, tolerability and clinical benefits versus PEG and other polymer-based technologies.

For more information on Serina Therapeutics, please visit www.serinatherapeutics.com.